Torrent Pharmaceuticals announced the resignation of its Executive Director, Amal Kelshikar, effective from October 16, 2026, at the close of business hours, according to a filing under Regulation 30 of SEBI Listing Regulations. Kelshikar had joined Torrent in May 2022 and served in the executive role for over four years.
Amal Kelshikar has nearly three decades of professional experience in the pharmaceutical and healthcare sectors. His career began at Novartis India as head of strategic planning and business development. He held leadership roles at Novartis Singapore and Novartis Philippines before moving to Baxter Healthcare as general manager. Kelshikar also served as president of AstraZeneca's Philippines subsidiary and held multiple senior positions at Abbott, including Managing Director for India and Divisional Vice President for Asia Pacific. Prior to joining Torrent, he was involved in business management consulting and a start-up mentorship program at the National University of Singapore Graduate Research Innovation Programme.
Kelshikar's resignation comes at a time when Torrent Pharmaceuticals continues to focus on expanding its footprint in the Indian pharmaceutical market. His extensive experience in strategic planning and leadership across Asia Pacific markets had been a key asset for the company. Torrent's disclosure of the resignation complies with SEBI regulations, reflecting transparency in corporate governance. The company has not announced a replacement yet, which is notable given Kelshikar's senior role and broad regional expertise.
Torrent Pharmaceuticals confirmed the resignation through its official filing on October 16, 2026. The company is expected to update stakeholders on its executive leadership in subsequent disclosures as per regulatory requirements.